2023
Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease
Ackley W, Dahl N, Park M. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. Advances In Kidney Disease And Health 2023, 30: 228-235. PMID: 37088525, DOI: 10.1053/j.akdh.2023.02.002.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseEnd-stage kidney diseaseKidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseRapid progressionMechanism-specific treatmentsChronic kidney diseaseFourth leading causeTreatment of patientsPharmacologic managementLeading causeKidney disordersFDA approvalDiseaseTolvaptanProgressionTreatmentRiskMorbidityPatientsPathogenesisTherapy
2020
Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?
Patel DM, Dahl NK. Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand? Clinical Journal Of The American Society Of Nephrology 2020, 16: 3-5. PMID: 33376103, PMCID: PMC7792649, DOI: 10.2215/cjn.17981120.Peer-Reviewed Original Research
2018
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. Journal Of The American Society Of Nephrology 2018, 29: 2458-2470. PMID: 30228150, PMCID: PMC6171265, DOI: 10.1681/asn.2018060590.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseOpen-label extension studyProgressive autosomal dominant polycystic kidney diseaseFirst drug treatmentRenal protective measuresKidney function declineLiver enzyme elevationCare of patientsConfirmation of diagnosisEducation of patientsCounseling of patientsDominant polycystic kidney diseasePolycystic kidney diseaseTolvaptan treatmentProgressive diseaseEnzyme elevationFunction declineKidney diseaseClinical trialsGeneral practitionersDrug treatmentTreatment efficacyPatientsTolvaptanUS FoodSemaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment
Lee Y, Blount KL, Dai F, Thompson S, Scher JK, Bitterman S, Droher M, Herzog EL, Moeckel G, Karihaloo A, Dahl NK. Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment. Clinical And Experimental Nephrology 2018, 22: 906-916. PMID: 29453607, DOI: 10.1007/s10157-018-1542-x.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsAutosomal dominant polycystic kidney diseaseEnd-stage renal diseaseRenal fibrosisSEMA7A expressionADPKD patientsTolvaptan treatmentPolycystic kidney diseaseKidney diseaseNumber of PBMCsExpression of SEMA7ASubsequent renal fibrosisMarkers of inflammationRegulatory T cellsADPKD kidneysBlood mononuclear cellsImmunomodulating proteinsRenal diseaseMononuclear cellsSmall kidneysKidney fibrosisLiver fibrosisRenal cystsSemaphorin 7AT cells